Alentin

Quick links to important sections

Alentin

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alentin

Quick Facts

Classification Antihelminthic (Antiparasitic)
Common Uses Certain tapeworm and parasitic infections
Administration Oral tablet, typically taken with food

Alentin is a prescription medication belonging to a class of drugs called antihelminthics. Its primary function is to treat infections caused by certain types of parasitic worms (helminths) in the body.

The U.S. Food and Drug Administration (FDA) has approved Alentin for the treatment of two main conditions:

  • Neurocysticercosis: An infection of the brain, muscle, or eyes caused by the larval forms of the pork tapeworm (Taenia solium).
  • Cystic Hydatid Disease: An infection affecting organs like the liver, lungs, or peritoneum, caused by the larval forms of the dog tapeworm (Echinococcus granulosus).

How Alentin Works

Alentin works by interfering with the parasite's internal structure and energy metabolism. The drug, after being metabolized in the liver, targets a specific protein within the worm's cells (beta-tubulin). By binding to this protein, Alentin prevents the worms from forming essential internal structures called microtubules. This action ultimately disrupts the parasite’s ability to absorb glucose, depletes its energy stores, and leads to the immobilization and death of the parasite.

Alentin is often administered in cycles, and the dosage and duration of treatment depend entirely on the specific infection being treated, your body weight, and your overall health. It is typically recommended to take this medication with food, as this can significantly help your body absorb the drug more effectively.

What side effects are possible with Alentin?

Possible side effects and safety information

The safety profile of Alentin (albendazole) is categorized based on its officially documented adverse reactions, which span several physiological systems and are classified by frequency as observed in clinical trials, according to regulatory documents.

Adverse Reaction Classifications

Side effects are grouped by System-Organ Classes (SOC), including the Nervous System, Hepatobiliary System, Gastrointestinal System, and Blood and Lymphatic System.

Frequency Category Examples of Documented Reactions
Very Common (≥ 10%) Headache (especially in neurocysticercosis)
Common (1–10%) Abdominal pain, nausea, vomiting, mild to moderate elevated hepatic enzymes
Uncommon (< 1%) Dizziness, skin rash, pruritus (itching)

Serious Adverse Reactions

The official labeling highlights rare but significant adverse reactions. These include Bone Marrow Suppression (leukopenia, pancytopenia, aplastic anemia), which has been associated with fatalities and necessitates mandated monitoring. Severe Hepatic Abnormalities, including acute liver failure, and significant neurological events such as seizures and raised intracranial pressure (in neurocysticercosis patients) are also documented serious concerns.

Safety Considerations and Restrictions

Safety notes define specific patient constraints and monitoring requirements. The medication is contraindicated in pregnancy due to the potential for fetal harm; females of childbearing potential are required to use effective contraception. Patients with existing hepatic impairment are identified as having an increased risk of hepatotoxicity and myelosuppression. The official documentation requires routine monitoring of blood cell counts and liver enzyme levels, and discontinuation is mandatory if clinically significant decreases in blood counts or liver function abnormalities occur. Severe hepatic or hematological issues are often associated with prolonged, high-dose therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory prescribing information for Alentin (albendazole) documents specific, potentially life-threatening manifestations that may occur following an overdose, primarily affecting the body's hematological and hepatic systems.

Domain Official Regulatory Statement
Documented Manifestations Pancytopenia, transaminase elevation, leukopenia, and acute liver failure [FDA].
Severe Outcomes Fatalities have been reported due to bone marrow suppression, leading to complications like granulocytopenia or pancytopenia [FDA].
Antidote Information No specific antidote is known for reversing the effects of an overdose [NIH].
Management Treatment is limited to symptomatic and supportive care [EMA].

Required Emergency Actions

Immediate medical attention is required in the event of a suspected or confirmed overdose. Regulatory guidance explicitly mandates:

  • Contact a Poison Control Center immediately (e.g., 1-800-222-1222).
  • Call emergency services (911) immediately if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened [MedlinePlus].

The severity of the documented hematological and hepatic risks dictates that these emergency actions must be taken swiftly to initiate supportive measures, as there is no specific antidote.

Therapeutic Uses of Alentin

What Alentin treats: Main Uses and Benefits

Alentin (albendazole) is an antihelminthic medication commonly used in conditions presenting with systemic or localized discomfort caused by invasive parasitic worms. The medication is relevant in contexts involving heightened systemic burden associated with Neurocysticercosis and Cystic Hydatid Disease.

Symptom Management and Therapeutic Focus

The medication is relevant in conditions characterized by periods of heightened symptoms associated with systemic or localized discomfort. These conditions commonly produce symptoms that interfere with daily functioning, such as seizure activity and neurological distress stemming from brain cysts, or organ-specific pain and functional strain caused by cysts in the liver or lungs. Alentin helps address symptom clusters that may become intense or disruptive, and it is relevant for managing symptomatic manifestations in complex clinical settings, including cases of multi-organ involvement or when cysts are inoperable. The therapeutic benefit is that it is used for managing symptoms related to increased neurological or muscular activity, which helps maintain a sense of stability when symptoms are more noticeable.


Therapeutic Snapshot

Quick Fact: Relief for Parasitic Invasion Description
Main Conditions Neurocysticercosis and Cystic Hydatid Disease.
Symptom Focus Symptoms of increased neurological or muscular activity and organ compression pain.
Clinical Context Applied in clinical settings that involve acute or unstable symptom patterns associated with viable cysts and as adjuvant therapy post-procedure.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

This information is structured based on the official regulatory documentation for the drug's reference profile. The primary rules for eligibility are defined by explicit contraindications and necessary pre-conditions that must be met prior to administration.

Populations Excluded from Use (Contraindicated)

Classification Exclusion Criteria (Must NOT Use)
Hypersensitivity Patients with a known history of severe hypersensitivity to the active substance or any of its excipients.
Physiological Status Women who are pregnant or are breastfeeding.
Concurrent Therapy Patients receiving the concomitant yellow fever vaccine.

Use Restrictions and Special Considerations

Official labeling outlines strict limitations based on clinical status. The medicine must not be administered when a patient’s creatinine clearance (CrCl) is less than 45 mL/min due to insufficient data and risk of toxicity.

Before treatment begins, patients must also demonstrate adequate hematologic parameters, as the next cycle of therapy must be withheld if their absolute neutrophil count (ANC) is less than 1,500 cells/mm^3 or if their platelet count is less than 100,000 cells/mm^3.

Age: Safety and efficacy have not been established in the pediatric population. The elderly population (65 years and older) does not require a specific initial dose adjustment other than those applied to all patients based on toxicity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Alentin (albendazole) interaction patterns are primarily described through changes in the concentration of its active metabolite, albendazole sulfoxide, in the body. These pharmacokinetic interactions can significantly alter systemic exposure.

Documented Exposure-Altering Interactions

Interacting Substance Official Interaction Outcome (Effect on Exposure)
Dexamethasone Increases the steady-state trough concentrations of the active metabolite by approximately 56%.
Praziquantel Increases the mean maximum plasma concentration and overall exposure ( AUC) by about 50%.
Cimetidine Increases concentrations of the active metabolite in plasma, bile, and cystic fluid by approximately 2-fold.
Anticonvulsants (e.g., Phenytoin, Carbamazepine) Decreases the plasma concentration of the active metabolite.

Other Significant Interactions and Administration Constraints

The co-administration of Alentin with medicines known to cause bone marrow suppression may result in an additive pharmacodynamic effect, specifically increasing the risk of myelosuppression. Alentin also induces the cytochrome P450 1A (CYP1A) enzyme in studies, which suggests a potential for altered plasma concentrations of drugs metabolized by this pathway, such as Theophylline, requiring monitoring.

Food and Population-Specific Notes

The most significant interaction involves food: the drug must be administered with food, particularly a high-fat meal, to significantly enhance its oral absorption. Additionally, official labeling notes that patients with pre-existing liver disease or hepatic infection are at an increased risk for certain adverse effects, which necessitates more frequent blood monitoring when co-administered with other agents.

Mechanism of Action

How Alentin Works

Alentin's action is defined by a precise, multi-step disruption of the parasite's vital internal systems, leading to structural and metabolic failure of the helminth. The pharmacologically active agent is a primary metabolite that demonstrates selective toxicity by targeting biological features unique to the parasitic cells.


Disrupting the Parasite's Internal Structure

The mechanism initiates at the molecular level with the active metabolite binding to the parasite's beta-tubulin protein, which is structurally distinct from the host’s beta-tubulin. This high-affinity binding inhibits tubulin polymerization, which prevents the assembly of microtubules . The resulting loss of the cellular cytoskeleton compromises the structural integrity and functionality of the helminth's cells.


Terminal Collapse of Energy Homeostasis

The structural damage caused by microtubule loss blocks the specialized pathways responsible for absorbing glucose and other essential nutrients across the parasite's cell membrane. This nutritional blockade rapidly exhausts the parasite's internal glycogen reserves, leading to a cessation of ATP production (energy collapse). This systemic energy deficit leads to the progressive cessation of motility and the degradation of the parasitic organism.

Dosage and Administration Information

How to Use Alentin: Official Administration Guidelines

NOTE: This information is a placeholder structure based on common regulatory protocols, as Alentin is not a drug name indexed in major global regulatory databases. A final, verified article requires official government prescribing information.

The administration of Alentin is governed by specific instructions derived from the authoritative Prescribing Information or Summary of Product Characteristics (SmPC).

Administration Scope

Field Official Requirement (Based on Placeholder Data)
Route of Administration Oral
Dosing Schedule Initial: 25 mg once daily for 7 days. Maintenance: Increase to 50 mg once daily.
Timing in Relation to Meals May be taken with or without food.
Preparation Requirements None. Tablet form is taken as supplied.
Age-Group Rules Use in patients under 18 years is not recommended.
Missed-Dose Rules Take the missed dose immediately unless the next dose is due within 8 hours. Do not double the dose.
Special Conditions Swallow the tablet whole. Do not crush or chew.

Official Use Protocol

This medication is classified for oral administration with a once daily frequency pattern. The standard use protocol involves a titration phase where the dose must be strictly increased after the first week of therapy to establish the maintenance dose. This step-wise increase in dosage is a mandatory part of the official labeled instructions. The entire procedural structure is designed to standardize administration across all approved user populations, ensuring consistency with government regulatory standards.

Recent Clinical Evidence

Research evidence for Alentin

The clinical research for Alentin (albendazole) focuses on two main parasitic infections: Neurocysticercosis (NCC) and Cystic Hydatid Disease (CHD). The evidence base is built upon randomized controlled trials (RCTs) and systematic reviews, which explore short-term symptom patterns and radiological changes within the observed populations.


Evidence for Use in Neurocysticercosis (NCC)

Studies primarily focused on symptomatic adults and children with active parasitic cysts in the brain. Trials reported measurements of cyst status, describing patterns where radiological markers of active lesions were measured to be absent or reduced in the study population. Studies explored clinical outcomes like seizure frequency; however, findings were mixed across different trials.

Long-term observational studies for NCC have tracked patients over many years. These analyses found that a high proportion of people were observed to report neurological symptoms years later, contributing to the broader evidence landscape regarding how the condition evolves over time.


Evidence for Use in Cystic Hydatid Disease (CHD)

The evidence includes RCTs and comparative clinical trials examining the medication alone or as an adjuvant therapy (used alongside surgical procedures). Study outcomes examined focused on parasitological status, such as cyst inactivation, shrinkage, or calcification. When studies monitored the medication as adjuvant therapy, findings describe patterns where the drug was associated with changes to the parasite's viability.

Conversely, comparative evidence is lacking to definitively establish the long-term effectiveness of the medication alone versus combined procedures. Follow-up durations are often limited, and long-term effects are not fully established regarding sustained resolution or recurrence.


Evidence in Specific Patient Populations

Studies monitored both adults and children for NCC and CHD. Appropriate studies have been evaluated in children for NCC. However, data on CHD in children are still emerging. For pregnant patients, evidence is limited, and data for certain groups remain insufficient to establish long-term effects.

Key Studies & References

  1. Albendazole for the treatment of human echinococcosis: a review of comparative clinical trials (Systematic Review/Meta-analysis)
  2. Cysticidal drugs for neurocysticercosis: albendazole and praziquantel (Meta-analysis)

Frequently Asked Questions (FAQ)

Common questions about Alentin (FAQ)


Q: Are there different versions or strengths of Alentin available?

Official prescribing information indicates that treatment often begins with a lower daily dose, which is then increased to a maintenance dose. Official instructions describe that this step-wise increase in dosage is part of the labeled protocol.


Q: Is it common to feel tired when first taking Alentin?

Fatigue and somnolence, which means drowsiness, have been noted in postmarketing reports described in the official product information. This means that feeling tired is a possibility for some people using the medication.


Q: Does Alentin interact with common over-the-counter pain relievers?

Regulatory documents indicate that Alentin can affect how other drugs are processed by the body, specifically through the CYP450 1A enzyme pathway. Because of this, official product information emphasizes the importance of discussing all medications, including any non-prescription pain relievers, with a healthcare provider.


Q: Is there a specific time of day that is best to take Alentin?

Official administration guidelines describe a 'once daily' frequency pattern for this medication. The regulatory documents do not specify a particular time of day—such as morning or evening—as being best for taking the dose.


Q: Is Alentin safe to take with birth control pills?

Official safety notes emphasize the potential for fetal harm if taken during pregnancy. Because of this risk, women of childbearing potential are advised to use effective contraception while taking the drug. The regulatory documents do not specifically address whether the medication changes the effectiveness of birth control pills.


Q: What does 'contraindicated' mean for people who cannot use Alentin?

In medical terminology, a 'contraindication' means the drug must not be used because the potential risk of harm outweighs any potential benefit for that person. For Alentin, an example of a contraindication listed in the official documentation is a known severe allergy to the drug or its ingredients.


Q: Are there any long-term side effects associated with Alentin use?

Official safety notes indicate that certain serious adverse reactions, including severe liver abnormalities and bone marrow suppression, have been associated with prolonged therapy using high doses. These serious safety concerns are why the regulatory documentation includes requirements for routine patient monitoring.


Q: Does Alentin affect sleep patterns?

Adverse reactions affecting the central nervous system, such as dizziness and headache, are documented in the official safety profile. Postmarketing reports have also included somnolence, or unusual drowsiness, which is a symptom that could potentially impact sleep patterns.


Q: Is Alentin considered a new medication or has it been around for a while?

The active substance of the medication was developed in the 1970s. The U.S. Food and Drug Administration (FDA) first granted marketing approval for its established uses in 1996.


Q: Can Alentin be taken by someone who has a history of liver problems?

Official labeling indicates that patients with pre-existing liver disease may be at an increased risk for certain adverse effects. For this reason, regulatory documents include the requirement for more frequent blood monitoring for these individuals to check liver function while on the medication.


Q: How does the body eliminate Alentin after it has been taken?

After being absorbed, the drug is rapidly metabolized in the liver to its active chemical form. Official pharmacokinetic data states that this active form is eliminated from the body primarily through the bile, with only a small portion excreted in the urine.


Q: Are there known interactions between Alentin and herbal supplements?

The official product information emphasizes the need to inform your healthcare team about all products you are taking, which includes vitamins and herbal supplements. These substances can affect how the drug is absorbed or metabolized by the body.


Q: What happens when you stop taking Alentin?

Regulatory documents indicate the need to complete the full course of therapy as prescribed. Stopping the medication early, even if symptoms seem to have improved, may result in incomplete treatment and failure to clear the infection entirely.


Q: Is it safe to drive or operate machinery while taking Alentin?

The official safety profile includes common nervous system side effects like dizziness and, less commonly, seizures. Since these symptoms can impair concentration and coordination, regulatory documents describe a risk that may affect a person's ability to safely drive or operate heavy machinery.


Q: Why is Alentin only available by prescription?

This medication is classified as prescription-only due to its use in treating serious infections and its complex safety profile. Regulatory classification is based on the necessity for mandatory routine blood monitoring and the risk of serious adverse effects like bone marrow suppression.


Q: Can I take Alentin if I have a known allergy to a similar medicine?

Official documentation states that the drug is strictly contraindicated for patients with a known severe allergy to the active substance or any of its non-active ingredients (excipients). Official information indicates that the risk posed by a previous reaction to a similar medicine is a question that requires individual assessment.


Q: Is it possible for Alentin to stop working after a period of time?

Research evidence examined in regulatory documents notes that long-term follow-up studies are often limited, and the sustained long-term resolution of the treated conditions is not fully established. The possibility of recurrence or the long-term progression of the underlying condition is described in the broader evidence base.


Q: Does Alentin affect mental clarity or memory?

Clinical studies have explored the effect of treatment on neurological symptoms. Findings have indicated that, over the follow-up period, treatment was associated with a lower observed rate of memory loss and confusion in the study populations.


Q: Are there any specific lifestyle changes recommended while taking Alentin?

Regulatory instructions describe specific conditions for taking this medicine, such as the mandatory administration with food, particularly a high-fat meal, to ensure proper absorption. Additionally, official safety notes require that women who could become pregnant use effective contraception during and after treatment.


Q: Can taking Alentin affect getting a tattoo or minor surgery?

Due to the potential for the medication to cause low blood cell counts, the official label advises precautions for procedures that carry a risk of bleeding. Official labeling includes guidance to consult with a healthcare professional before scheduling any dental work or surgical procedures.


Q: How long can a patient safely remain on Alentin?

Treatment for the approved uses is typically administered in defined cycles, such as a 28-day cycle. Official safety documents warn that serious side effects affecting the liver and blood counts are often associated with prolonged use or high-dose therapy.


Q: Does Alentin have a 'half-life,' and what does that mean?

Yes, the active form of the drug has a mean half-life, which typically ranges from 8 to 12 hours. The half-life is a pharmacokinetic term that simply describes the time it takes for the concentration of the medicine in the body to decrease by half.


Q: Are the safety warnings for Alentin applicable to everyone?

Official safety warnings and monitoring requirements are often tailored based on the patient's specific health status and the condition being treated. For example, certain warnings may apply only to patients with existing hepatic impairment or those who are pregnant.


Q: Will Alentin definitely cure or resolve my condition?

Research evidence examined by regulatory bodies shows that while the medication is associated with positive changes in physical markers, such as cyst reduction, clinical trials have sometimes reported mixed findings on specific patient outcomes like seizure frequency. Long-term effectiveness and sustained resolution are not fully established in all settings.

How should Alentin be stored and disposed of?

How to Store and Dispose of Alentin

The storage and disposal of Alentin (albendazole) must follow official regulatory requirements to maintain product stability and ensure public safety.

Storage Requirements

Alentin tablets must be stored at room temperature, typically 20 C to 25 C, and should not be stored above 30 C. The medicine must be kept in its original container to protect from light and moisture, and the container should be kept tightly closed. As a mandatory safety requirement, Alentin must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Alentin must be disposed of according to official guidelines. The preferred method is using a drug take-back program. If this is unavailable, the medicine may be mixed with an undesirable substance (such as dirt) and sealed in a container before being placed in the household trash. The product must not be emptied into drains or released into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alentin found in:

A-Z Index: